全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Developing of Granulomatosis with Polyangiitis during Etanercept Therapy

DOI: 10.1155/2014/210108

Full-Text   Cite this paper   Add to My Lib

Abstract:

We describe a 67-year-old woman who developed c-ANCA positive vasculitis with involvement in eyes, skin, kidney, peripheral nerves, and upper and lower airway during treatment with etanercept therapy for rheumatoid arthritis. A diagnosis of Granulomatosis with Polyangiitis was done. Thus, anti-TNF therapy may be associated with the development of ANCA positive vasculitis. 1. Introduction The tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine involved in the pathogenesis of many inflammatory and autoimmune conditions as rheumatoid arthritis (RA) and inflammatory bowel disease among others. Several anti-TNF-α biological agents have been approved for the management of RA [1]. The most frequent adverse events related to anti-TNF-α therapies are infectious diseases, malignancies, demyelinating diseases, and drug-induced lupus [2, 3]. In addition, treatment with etanercept has been associated with the development of diverse granulomatous diseases such as sarcoidosis [4–6], granulomatous hepatitis [7], granulomatous thyroiditis [8], and Wegener’s granulomatosis (now denoted as Granulomatosis with Polyangiitis-GPA-) [9]. Here, we report a new case of GPA developing in a patient with RA treated with etanercept. 2. Case Report A 67-year-old woman was admitted in our service by a clinical picture of two weeks of new onset-very painful and erythematous nodules in lower limbs that were followed by ulceration. She additionally manifested constitutional symptoms, conjunctive injection, nasal congestion, paresthesia, and paresia in the lower limbs associated with peripheral neuropathy and polyarthritis. She had a 2-year history of RA refractory to treatment with prednisolone (10?mgr/day) and methotrexate (15?mgr/weekly). After 8 months of this treatment and because of high activity disease score, a treatment with subcutaneous etanercept (50?mg weekly) was initiated three months before admission. The physical examination at admission revealed bilateral conjunctive injection, and the ophthalmologic exam showed bilateral scleritis. Deformity in hands with synovitis and nodules in the right elbow extensor aspect was also observed. Ulcerated lesions with necrotic center in lower limbs were evident (Figure 1). Laboratory test showed normal hemoglobin (13?g/dL), high WBC, and platelets count (18,000/mL and 542,000/mL, resp.). No lymphopenia was found. Acute phase reactants were elevated, with an erythrosedimentation rate of 111?mm/hour and C-reactive protein of 15.3?mg/dL (normal <0.5?mg/dL). Renal and liver functions were normal. The autoantibodies profile

References

[1]  F. Conti, F. Ceccarelli, L. Massaro, et al., “Biological therapies in rheumatic diseases,” Clinical Therapeutics, vol. 164, no. 5, pp. e413–e428, 2013.
[2]  M. C. Hochberg, M. G. Lebwohl, S. E. Plevy, K. F. Hobbs, and D. E. Yocum, “The benefit/risk profile of TNF-blocking agents: findings of a consensus panel,” Seminars in Arthritis and Rheumatism, vol. 34, no. 6, pp. 819–836, 2005.
[3]  J. C. Diaz, S. Vallejo, and C. A. Ca?as, “Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab,” Rheumatology International, vol. 32, no. 10, pp. 3315–3317, 2012.
[4]  T. Ishiguro, N. Takayanagi, K. Kurashima et al., “Development of sarcoidosis during etanercept therapy,” Internal Medicine, vol. 47, no. 11, pp. 1021–1025, 2008.
[5]  K. E. Hostettler, U. Studler, M. Tamm, and M. H. Brutsche, “Long-term treatment with infliximab in patients with sarcoidosis,” Respiration, vol. 83, no. 3, pp. 218–224, 2012.
[6]  A. Kudrin, E. R. Chilvers, A. Ginawi et al., “Sarcoid-like granulomatous disease following etanercept treatment for rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 3, pp. 648–649, 2007.
[7]  M. Farah, A. Al Rashidi, D. A. Owen, E. M. Yoshida, and G. D. Reid, “Granulomatous hepatitis associated with etanercept therapy,” Journal of Rheumatology, vol. 35, no. 2, pp. 349–351, 2008.
[8]  C. A. Ca?as, G. J. Tobón, L. G. Arango, and N. Guarín, “Developing of granulomatous thyroiditis during etanercept therapy,” Clinical Rheumatology, vol. 28, supplement 1, pp. S17–S19, 2009.
[9]  V. Broshtilova, E. Iliev, and M. Gantcheva, “Etanercept-induced Wegener granulomatosis in a patient with rheumatoid arthritis,” Dermatologic Therapy, vol. 26, pp. 73–76, 2013.
[10]  R. Y. Leavitt, A. S. Fauci, D. A. Bloch et al., “The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis,” Arthritis and Rheumatism, vol. 33, no. 8, pp. 1101–1107, 1990.
[11]  H. Tadema, P. Heeringa, and C. G. M. Kallenberg, “Bacterial infections in Wegener's granulomatosis: mechanisms potentially involved in autoimmune pathogenesis,” Current Opinion in Rheumatology, vol. 23, no. 4, pp. 366–371, 2011.
[12]  B. Scallon, A. Cai, N. Solowski et al., “Binding and functional comparisons of two types of tumor necrosis factor antagonists,” Journal of Pharmacology and Experimental Therapeutics, vol. 301, no. 2, pp. 418–426, 2002.
[13]  K. Parekh, D. Ching, M. U. Rahman, and L. K. Stamp, “Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event?” Rheumatology, vol. 49, no. 9, pp. 1785–1787, 2010.
[14]  A. Massara, L. Cavazzini, R. La Corte, and F. Trotta, “Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new “class effect” paradoxical phenomenon. Two case reports and literature review,” Seminars in Arthritis and Rheumatism, vol. 39, no. 4, pp. 313–319, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133